Santa Clara, CA and
Cambridge, UK (November 06 2012) – Crown Bioscience, Inc., a leading global
drug discovery and development service company, and Horizon Discovery Ltd., a leading provider of
research tools to support the development of personalized medicines, will highlight the availability of X-MAN™ cell lines for in vitro and in vivo drug
discovery model validation at the 24th EORTC - NCI - AACR Symposium on
Molecular Targets and Cancer Therapeutics, Dublin, Nov 6-9, 2012.
High-quality human
disease models are crucial for generating 'first-in-class' patient-relevant targets
and facilitating the development of novel oncology targets and early-stage drug
discovery programs within the pharmaceutical industry. The new in vivo
X-MAN (X-Gene Mutant And Normal) models will be made available to
customers by Crown Bioscience via a new service offering whilst Horizon will
provide access to a broad range of in
vitro services based around its inventory of; >450 X-MAN cell lines,
>50 phenotypic cell-based assays and its SyntheTx™
drug/RNAi screening platform.
Leveraging their unique
drug discovery and translational research platforms, Crown Bioscience and
Horizon Discovery help develop the best drug candidates with high confidence
for clinical development, reducing drug attrition and development cost. Crown
Bioscience and Horizon Discovery are ideally placed to help bring to the clinic
lead molecules based upon highly validated and novel drug models. The in vitro and in vivo cell lines are available to clients who want to help
validate new models and become early adopters with full access to new models at
the earliest possible phase.
“Crown Bioscience aspires to become the innovation
engine for the global biotech and pharmaceutical industry. We are guided by our
responsibility to clients and a desire to make a major positive impact on human
life worldwide. We are constantly pioneering new paths and finding new answers
to meet the urgent needs of our customers’ waging war against cancer,” said Jean-Pierre
Wery, President of Crown Bioscience. “The novel in vivo models we are developing based on the X-MANTM cell lines offer new opportunities for
clients to collaborate with us at an early stage and validate the models based
on their needs, This will allow greater insights and better means to evaluate
the therapeutic efficacy of compounds and their impact on key physiological
functions.”
“Horizon Discovery uses
its highly efficient and proprietary gene-engineering platform technology,
GENESIS™ to precisely engineer X-MAN human disease models
that harbor the key genetic features that drive a patient’s disease” commented Darrin
Disley, CEO of Horizon Discovery. “We are delighted to provide Crown Bioscience
with our unique range of X-MAN cell lines, so that Crown can develop and provide
our clients with a suite of in vivo models
that complements our extensive range of in
vitro services.”
The new in vivo models
demonstrate Crown Bioscience’s commitment to continuing to invest in and expand
its portfolio of models and to work collaboratively
with partners and clients to accurately and robustly evaluate the efficacy of
new therapeutic agents. The in
vivo models are designed to help clients address their key needs and
challenges by providing cutting-edge clinically relevant models that are ready
to run. Crown Bioscience’s comprehensive
services for drug development, from target to pre-IND, have accelerated
confident Go/No Go decisions during early stage drug discovery and ensured
robust pre-clinical candidate selection.
To learn more please
visit Crown Bioscience at booth #C3 and Horizon Discovery at booth #A4 at the
24th EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics,
Dublin, Nov 6-9, 2012.
Alternatively please
email pr@mail.crownbio.com, call 001 408 986 0103 or visit www.crownbio.com
(for Crown Bioscience Inc) or xman@horizondiscovery.com, call
0044 1223 655 580 or visit www.horizondiscovery.com (for
Horizon Discovery Ltd)
